Cargando…
3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders
Antidepressants are psychiatric agents used for the treatment of different types of depression being at present amongst the most commonly prescribed drug, while their effectiveness and adverse effects are the subject of many studies and competing claims. Having studied five QSAR models predicting th...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Österreichische Apotheker-Verlagsgesellschaft
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002802/ https://www.ncbi.nlm.nih.gov/pubmed/21179345 http://dx.doi.org/10.3797/scipharm.0912-22 |
_version_ | 1782193786632273920 |
---|---|
author | Avram, Speranta Buiu, Catalin Duda-Seiman, Daniel M. Duda-Seiman, Corina Mihailescu, Dan |
author_facet | Avram, Speranta Buiu, Catalin Duda-Seiman, Daniel M. Duda-Seiman, Corina Mihailescu, Dan |
author_sort | Avram, Speranta |
collection | PubMed |
description | Antidepressants are psychiatric agents used for the treatment of different types of depression being at present amongst the most commonly prescribed drug, while their effectiveness and adverse effects are the subject of many studies and competing claims. Having studied five QSAR models predicting the biological activities of 18 antidepressants, already approved for clinical treatment, in interaction with the serotonin transporter (SERT), we attempted to establish the membrane ions’ contributions (sodium, potassium, chlorine and calcium) supplied by donor/acceptor hydrogen bond character and electrostatic field to the antidepressant activity. Significant cross-validated correlation q(2) (0.5–0.6) and the fitted correlation r(2) (0.7–0.82) coefficients were obtained indicating that the models can predict the antidepressant activity of compounds. Moreover, considering the contribution of membrane ions (sodium, potassium and calcium) and hydrogen bond donor character, we have proposed a library of 24 new escitalopram structures, some of them probably with significantly improved antidepressant activity in comparison with the parent compound. |
format | Text |
id | pubmed-3002802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Österreichische Apotheker-Verlagsgesellschaft |
record_format | MEDLINE/PubMed |
spelling | pubmed-30028022010-12-22 3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders Avram, Speranta Buiu, Catalin Duda-Seiman, Daniel M. Duda-Seiman, Corina Mihailescu, Dan Sci Pharm Original Paper Antidepressants are psychiatric agents used for the treatment of different types of depression being at present amongst the most commonly prescribed drug, while their effectiveness and adverse effects are the subject of many studies and competing claims. Having studied five QSAR models predicting the biological activities of 18 antidepressants, already approved for clinical treatment, in interaction with the serotonin transporter (SERT), we attempted to establish the membrane ions’ contributions (sodium, potassium, chlorine and calcium) supplied by donor/acceptor hydrogen bond character and electrostatic field to the antidepressant activity. Significant cross-validated correlation q(2) (0.5–0.6) and the fitted correlation r(2) (0.7–0.82) coefficients were obtained indicating that the models can predict the antidepressant activity of compounds. Moreover, considering the contribution of membrane ions (sodium, potassium and calcium) and hydrogen bond donor character, we have proposed a library of 24 new escitalopram structures, some of them probably with significantly improved antidepressant activity in comparison with the parent compound. Österreichische Apotheker-Verlagsgesellschaft 2010 2010-05-05 /pmc/articles/PMC3002802/ /pubmed/21179345 http://dx.doi.org/10.3797/scipharm.0912-22 Text en © Avram et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Paper Avram, Speranta Buiu, Catalin Duda-Seiman, Daniel M. Duda-Seiman, Corina Mihailescu, Dan 3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders |
title | 3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders |
title_full | 3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders |
title_fullStr | 3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders |
title_full_unstemmed | 3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders |
title_short | 3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders |
title_sort | 3d-qsar design of new escitalopram derivatives for the treatment of major depressive disorders |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002802/ https://www.ncbi.nlm.nih.gov/pubmed/21179345 http://dx.doi.org/10.3797/scipharm.0912-22 |
work_keys_str_mv | AT avramsperanta 3dqsardesignofnewescitalopramderivativesforthetreatmentofmajordepressivedisorders AT buiucatalin 3dqsardesignofnewescitalopramderivativesforthetreatmentofmajordepressivedisorders AT dudaseimandanielm 3dqsardesignofnewescitalopramderivativesforthetreatmentofmajordepressivedisorders AT dudaseimancorina 3dqsardesignofnewescitalopramderivativesforthetreatmentofmajordepressivedisorders AT mihailescudan 3dqsardesignofnewescitalopramderivativesforthetreatmentofmajordepressivedisorders |